A governance-first AI screen for health and life sciences

Few sectors have more to gain from AI than health and life sciences, and few have less tolerance for getting governance wrong. The opportunity is real — vast clinical, regulatory, and scientific knowledge that no person can fully hold in their head, spread across systems that do not talk to each other — but the value is realized only through systems that are compliant, grounded, and auditable by design, not by afterthought.

Where AI creates value

• Governed knowledge. Grounded, cited answers over clinical, regulatory, and institutional knowledge, permission-aware by design, so a question is answered with exactly the information the person asking is authorized to see.
• Research & literature support. Faster synthesis of large document sets (trial data, regulatory filings, and published literature) with citations back to source so a reviewer can verify every claim.
• Field & commercial enablement. Accurate, compliant answers for field teams working within tight rules on what can and cannot be said, without waiting on medical affairs for every question.

Why governance is harder here

Health and life sciences carry a stack of constraints most industries do not face simultaneously: patient privacy regulation, regulatory oversight of promotional and clinical claims, and a professional culture, rightly skeptical of confident-sounding answers that turn out to be wrong. A system built for a retail business can tolerate an occasional bad answer as a minor annoyance. A system touching clinical or regulatory content cannot, which changes the engineering bar for evaluation, access control, and human review before anything reaches production.

That is also why “move fast and iterate in production” is the wrong posture. Iteration still happens on evaluation sets, prompt constraints, and retrieval quality, but behind a review gate appropriate to the risk class of the content.

What a defensible system looks like

The organizations that get this right build in the controls from day one rather than retrofitting them after a close call: every answer traceable to a specific, versioned source document; retrieval that respects role-based access so sensitive research or unapproved materials never surface outside the team cleared to see them; a human-review checkpoint for anything that touches clinical guidance, regulatory submissions, or promotional claims; and logging detailed enough to reconstruct exactly what the system said, to whom, and based on what source, months later if a regulator asks.

Field enablement deserves special care. A system that helps a commercial team answer on-label questions faster is valuable. A system that invents comparative claims or invents citations is a compliance incident. Scope the corpus tightly, refuse when retrieval is weak, and keep medical-legal review in the loop for anything that could be promotional.

Where not to start

Do not begin with autonomous clinical decision-making, open-ended patient-facing advice, or any workflow where a wrong answer creates immediate clinical risk without a qualified human in control. Start with internal knowledge, literature synthesis with citations, or controlled field Q&A over approved materials. Those workflows build organizational trust in grounding and audit trails before you expand the risk envelope.

Clearance is not the same as evidence. A 2025 JAMA Network Open review of 903 AI-enabled medical devices on the FDA’s list found that 24.1% explicitly reported no clinical performance study at the time of approval, and that of the 505 which did report one, just 12 used a randomized design. If that is the evidence base for devices that went through regulatory review, an internal deployment that went through none deserves more scrutiny, not less. In health and life sciences, the path to a defensible system runs through governance discipline, not around it. Programs that treat compliance as a launch checklist item tend to die in legal review or, worse, after a public mistake.

Governance is the enabler, not the blocker

The organizations that succeed treat data handling, access control, and evaluation as the foundation, not an afterthought bolted on before a launch date. That is what makes a system safe to put in front of a regulator, an auditor, or a skeptical clinician, and it is usually faster in the long run than moving quickly and then having to rebuild trust after a mistake. Start with Zero Data Retention and confidentiality to understand the baseline requirements before evaluating any platform.

See how this maps to your organization on our Health & Life Sciences page, and start with an AI Decision Sprint built around a full governance review.

Five gates before a pilot

1. Intended use: state whether the output informs research, operations, commercial work, or a regulated or clinical decision.
2. Evidence boundary: identify the authoritative sources, freshness requirement, and citation standard.
3. Data boundary: classify personal, clinical, proprietary, and partner data before choosing a provider or feature.
4. Human accountability: name who reviews the output, what they must verify, and when automation is prohibited.
5. Change control: define evaluation and approval required after model, prompt, source, or workflow changes.

A use case that cannot pass the first three gates is not ready for technical discovery. A use case that passes them may still be valuable even if the first implementation remains internal and assistive.

Sources

• Mohammadi Kazaj et al., “Generalizability of FDA-Approved AI-Enabled Medical Devices for Clinical Use,” JAMA Network Open, 2025
• NIST, “AI Risk Management Framework: Generative AI Profile”

Accessed July 2026. Vendor terms and benchmark methodologies change; verify current primary documentation before making a decision.